Exact Sciences‘ Oncodetect molecular residual disease (MRD) test has received Medicare coverage through the Centers for Medicare & Medicaid Services (CMS) Molecular Diagnostic Services Program (MolDX), the company announced recently.

According to a release, the test for serial use in patients with stage II, III and resectable stage IV colorectal cancer (CRC) in the adjuvant and recurrence monitoring settings over a five-year period.

“Gaining Medicare coverage for the Oncodetect test is a meaningful step forward in expanding access to earlier, more personalized insights for patients with colorectal cancer,” Exact Sciences Executive Vice President and General Manager, Precision Oncology Brian Baranick said in a statement. “This decision underscores the clinical value of our MRD test and reinforces Exact Sciences’ leadership in advancing tools that support timely, informed treatment decisions.”

Exact Sciences is also pursuing additional Medicare coverage across other solid tumor indications.